Sanofi gets binding bids for consumer unit
The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...
French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...